z-logo
open-access-imgOpen Access
Glyoxylate reductase activity in blood mononuclear cells and the diagnosis of primary hyperoxaluria type 2
Author(s) -
John Knight,
Ross P. Holmes,
Dawn S. Milliner,
Carla G. Monico,
Scott D. Cramer
Publication year - 2006
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfl142
Subject(s) - primary hyperoxaluria , medicine , nephrocalcinosis , oxalate , endocrinology , excretion , urinary system , glyoxylate cycle , gastroenterology , urine , pathology , kidney , metabolism , chemistry , organic chemistry
Primary hyperoxaluria type 2 (PH2) is a rare monogenic disorder characterized by an elevated urinary excretion of oxalate. Increased oxalate excretion in PH2 patients can cause nephrolithiasis and nephrocalcinosis, and can, in some cases, result in renal failure and systemic oxalate deposition. The disease is due to a deficiency of glyoxylate reductase/hydroxypyruvate reductase (GRHPR) activity. A definitive diagnosis of PH2 is currently made by the analysis of GR activity in a liver biopsy. GRHPR is expressed in virtually every tissue in the body, suggesting that utilization of more readily available cells could be used to determine GRHPR deficiency. In this study, we have evaluated the potential of determining GR and d-glycerate dehydrogenase (DGDH) activity in blood mononuclear cells (BMC) as a diagnostic indicator of PH2.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom